丁螺环酮、阿立哌唑合并利培酮治疗精神分裂症患者的疗效及对患者阴性症状及认知功能的影响
Efficacy of buspirone, aripiprazole combined with risperidone in the treatment of schizophrenia and its effect on negative symptoms and cognitive function
ES评分 0
| DOI |
| 刊名 |
Journal of International Psychiatry
|
| 年，卷(期) |
2019, 46(3) |
| 作者 |
|
| 作者单位 |
北京市房山区精神卫生保健院精神科 ;
|
| 摘要 |
【摘要】 研究丁螺环酮、阿立哌唑合并利培酮治疗精神分裂症患者的疗效及对患者阴性症状及认知功能的影响。方法 选取2015年5月~2018年5月我院收治的152例精神分裂症患者为研究对象，以随机数字表法将其分为对照组（76例）和观察组（76例）。对照组患者采用阿立哌唑合并利培酮治疗，观察组患者采用丁螺环酮合并利培酮治疗。两组患者连续治疗3个月后，比较两组患者临床疗效、阴性症状、认知功能以及不良反应发生情况。结果 观察组患者临床疗效总有效率显著高于对照组，差异有统计学意义（P﹤0.05）。两组患者治疗前SANS评分、CASI评分比较差异无统计学意义（P>0.05）；两组患者治疗后SANS评分、CASI评分均有显著改善，差异有统计学意义（P﹤0.05）；且治疗后观察组SANS评分显著低于对照组，差异有统计学意义（P﹤0.05）；治疗后观察组CASI评分显著高于对照组，差异有统计学意义（P﹤0.05）。观察组患者总不良反应发生率显著低于对照组，差异有统计学意义（P﹤0.05）。结论 丁螺环酮合并利培酮治疗精神分裂症具有良好临床疗效，可有效改善患者阴性症状、认知功能，且安全性较高。
|
| Abstract |
【Abstract】 Objective To study the efficacy of buspirone and aripiprazole combined with risperidone in the treatment of schizophrenia and its negative symptoms and cognitive function.Methods 152 schizophrenic patients admitted to our hospital from May 2015 to May 2018 were selected and randomly divided into control group (76 cases) and observation group (76 cases) by random digital table method.The patients in the control group were treated with aripiprazole combined with risperidone, and the patients in the observation group were treated with buspirone combined with risperidone.After 3 months of continuous treatment, the clinical efficacy, negative symptoms, cognitive function and adverse reactions were compared between the two groups.Results The total effective rate in the observation group was significantly higher than that in the control group, the difference was statistically significant (P﹤0.05). There was no significant difference in SANS score and CASI score between the two groups before treatment (P>0.05), but there was significant improvement in SANS score and CASI score after treatment between the two groups, the difference was statistically significant (P﹤0.05). The SANS score of the observation group was significantly lower than that of the control group after treatment, the difference was statistically significant (P﹤0.05). The CASI score of the observation group was significantly higher than that of the control group after treatment, the difference was statistically significant (P﹤0.05). The incidence of total adverse reactions in the observation group was significantly lower than that in the control group, the difference was statistically significant (P﹤0.05). Conclusion Buspirone combined with risperidone has a good clinical efficacy in the treatment of schizophrenia, can effectively improve the negative symptoms, cognitive function, and high safety.
|
| 关键词 |
【关键词】 丁螺环酮；阿立哌唑；利培酮；精神分裂症；疗效；阴性症状；认知功能
|
| KeyWord |
【keywords】 Buspirone; aripiprazole; risperidone; schizophrenia; efficacy; negative symptoms; cognitive function
|
| 基金项目 |
|
| 页码 |
460-462 |
张长春*.
丁螺环酮、阿立哌唑合并利培酮治疗精神分裂症患者的疗效及对患者阴性症状及认知功能的影响 [J].
国际精神病学杂志.
2019; 46; (3).
460 - 462.